(New York, USA) DelveInsight’s “Acanthamoeba Keratitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Acanthamoeba Keratitis, historical and forecasted epidemiology as well as the Acanthamoeba Keratitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Acanthamoeba Keratitis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Acanthamoeba Keratitis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Acanthamoeba Keratitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Acanthamoeba Keratitis market.
Request for a Free Sample Report @ Acanthamoeba Keratitis Market Forecast
Some facts of the Acanthamoeba Keratitis Market Report are:
- According to DelveInsight, Acanthamoeba Keratitis market size is expected to grow at a decent CAGR by 2032.
- Leading Acanthamoeba Keratitis companies working in the market are Allergan, Merck Sharp & Dohme Corp., Pfizer Inc., GlaxoSmithKline plc, SIFI SpA, Cipla Inc., AstraZeneca, Johnson & Johnson Private Limited, Basilea Pharmaceutica Ltd., Tetraphase Pharmaceuticals, Paratek Pharmaceuticals, Inc., Nabriva Therapeutics plc, Spero Therapeutics, Abbott, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Bayer AG, Sun Pharmaceutical Industries Ltd., Lilly, Aurobindo Pharma, Lupin, SHIONOGI & Co., Ltd., AbbVie Inc, and others.
- Key Acanthamoeba Keratitis Therapies expected to launch in the market are Propamidine, PHMB 0.02%, and others.
- Although Acanthamoeba keratitis is uncommon, it can cause eye pain, permanent vision loss, and even blindness
- In the 7MM countries, the incidence of Acanthamoeba keratitis is approximately 1 to 33 cases per million contact lens wearers
- In the United States, the prevalence of Acanthamoeba keratitis is 1 to 2 new cases per million contact lens wearers.
- It is evaluated that, approximately 16.7% of the US adults wear contact lenses
Acanthamoeba Keratitis Overview
Acanthamoeba keratitis is a rare, but serious, eye infection caused by Acanthamoeba, a free-living amoeba found in water, soil, and air. It primarily affects the cornea, the transparent outer covering of the eye, and can lead to severe pain, visual impairment, and potentially blindness if not promptly treated.
The infection is most commonly associated with contact lens wearers, especially those who practice poor lens hygiene, use contaminated water for lens cleaning, or swim while wearing lenses. Symptoms of Acanthamoeba keratitis include severe eye pain, redness, blurred vision, sensitivity to light (photophobia), a sensation of something in the eye, and excessive tearing.
Diagnosis involves a thorough clinical examination, including the use of specialized staining techniques and culture methods to detect the presence of Acanthamoeba in corneal scrapings. Advanced imaging techniques like confocal microscopy may also be used.
Treatment is challenging and often prolonged, involving a combination of topical anti-amoebic medications such as polyhexamethylene biguanide (PHMB) and chlorhexidine. In severe cases, surgical interventions like corneal transplantation may be necessary.
Preventive measures are crucial for contact lens users, including proper lens cleaning and storage, avoiding contact with water while wearing lenses, and adhering to recommended lens replacement schedules. Early diagnosis and aggressive treatment are essential to improving outcomes and preserving vision in patients with Acanthamoeba keratitis.
Learn more about Acanthamoeba Keratitis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Acanthamoeba Keratitis Prevalence
Acanthamoeba Keratitis Market
The Acanthamoeba Keratitis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Acanthamoeba Keratitis market trends by analyzing the impact of current Acanthamoeba Keratitis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Acanthamoeba Keratitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Acanthamoeba Keratitis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Acanthamoeba Keratitis market in 7MM is expected to witness a major change in the study period 2019-2032.
Acanthamoeba Keratitis Epidemiology
The Acanthamoeba Keratitis epidemiology section provides insights into the historical and current Acanthamoeba Keratitis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acanthamoeba Keratitis market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Acanthamoeba Keratitis Epidemiology @ Acanthamoeba Keratitis Treatment Market
Acanthamoeba Keratitis Drugs Uptake
This section focuses on the uptake rate of the potential Acanthamoeba Keratitis drugs recently launched in the Acanthamoeba Keratitis market or expected to be launched in 2019-2032. The analysis covers the Acanthamoeba Keratitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Acanthamoeba Keratitis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Acanthamoeba Keratitis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Acanthamoeba Keratitis Pipeline Development Activities
The Acanthamoeba Keratitis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acanthamoeba Keratitis key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Acanthamoeba Keratitis pipeline development activities @ Acanthamoeba Keratitis Therapies and Drugs
Acanthamoeba Keratitis Therapeutics Assessment
Major key companies are working proactively in the Acanthamoeba Keratitis Therapeutics market to develop novel therapies which will drive the Acanthamoeba Keratitis treatment markets in the upcoming years are are Allergan, Merck Sharp & Dohme Corp., Pfizer Inc., GlaxoSmithKline plc, SIFI SpA, Cipla Inc., AstraZeneca, Johnson & Johnson Private Limited, Basilea Pharmaceutica Ltd., Tetraphase Pharmaceuticals, Paratek Pharmaceuticals, Inc., Nabriva Therapeutics plc, Spero Therapeutics, Abbott, F. Hoffmann-La Roche Ltd., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi, Novartis AG, Bayer AG, Sun Pharmaceutical Industries Ltd., Lilly, Aurobindo Pharma, Lupin, SHIONOGI & Co., Ltd., AbbVie Inc, and others.
Learn more about the emerging Acanthamoeba Keratitis therapies & key companies @ Acanthamoeba Keratitis clinical trials and FDA Approvals
Acanthamoeba Keratitis Report Key Insights
1. Acanthamoeba Keratitis Patient Population
2. Acanthamoeba Keratitis Market Size and Trends
3. Key Cross Competition in the Acanthamoeba Keratitis Market
4. Acanthamoeba Keratitis Market Dynamics (Key Drivers and Barriers)
5. Acanthamoeba Keratitis Market Opportunities
6. Acanthamoeba Keratitis Therapeutic Approaches
7. Acanthamoeba Keratitis Pipeline Analysis
8. Acanthamoeba Keratitis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Acanthamoeba Keratitis Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Acanthamoeba Keratitis Competitive Intelligence Analysis
4. Acanthamoeba Keratitis Market Overview at a Glance
5. Acanthamoeba Keratitis Disease Background and Overview
6. Acanthamoeba Keratitis Patient Journey
7. Acanthamoeba Keratitis Epidemiology and Patient Population
8. Acanthamoeba Keratitis Treatment Algorithm, Current Treatment, and Medical Practices
9. Acanthamoeba Keratitis Unmet Needs
10. Key Endpoints of Acanthamoeba Keratitis Treatment
11. Acanthamoeba Keratitis Marketed Products
12. Acanthamoeba Keratitis Emerging Therapies
13. Acanthamoeba Keratitis Seven Major Market Analysis
14. Attribute Analysis
15. Acanthamoeba Keratitis Market Outlook (7 major markets)
16. Acanthamoeba Keratitis Access and Reimbursement Overview
17. KOL Views on the Acanthamoeba Keratitis Market
18. Acanthamoeba Keratitis Market Drivers
19. Acanthamoeba Keratitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services